KRAS ACTIVATING MUTATION
Clinical trials for KRAS ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for KRAS ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets hard-to-treat lung cancer mutation
Disease control OngoingThis study tests a combination of two or three experimental drugs (avutometinib, sotorasib, and defactinib) in people with a specific type of advanced lung cancer called KRAS G12C non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the …
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
New hope for pancreatic cancer: drug combo trial underway
Disease control OngoingThis study tests whether adding two experimental drugs (avutometinib and defactinib) to standard chemotherapy can help people with advanced pancreatic cancer that has spread. About 40 adults with untreated metastatic pancreatic cancer will take part. The goal is to see if the com…
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC